Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Waiyi Zou"'
Autor:
Hong Chen, Yan Wen, Yun Zeng, Lie Lin, Bihong Sun, Hongqian Zhu, Huiqing He, Xiaotao Wang, Waiyi Zou, Caifeng Zheng, Liling Zheng, Jinxiong Huang, Liping Pang, Jixian Huang, Yuming Zhang, Haiqing Lin, Zelin Liu, Wanshou Zhu, Qiang Wang, Xuan Zhou, Xiaoli Liu, Hong Qu, Zhenfang Liu, Xin Du, Na Xu
Publikováno v:
Oncology and Therapy, Vol 12, Iss 1, Pp 131-145 (2023)
Abstract Introduction Chronic myeloid leukemia (CML) is a chronic disease with treatment-free remission (TFR) increasingly regarded as a feasible goal of treatment. However, various factors may influence adherence to international guidelines for CML
Externí odkaz:
https://doaj.org/article/1a4339b229f24421b410fec79bd53d69
Publikováno v:
Cancer Medicine, Vol 10, Iss 21, Pp 7641-7649 (2021)
Abstract Background To evaluate the efficacy and safety of recombinant human thrombopoietin (rhTPO) for hematopoietic reconstitution after autologous stem cell transplant (ASCT) in patients with newly diagnosed multiple myeloma (NDMM). Method Thirty
Externí odkaz:
https://doaj.org/article/f69ed93865e94f38b56642c25e001bd7
Publikováno v:
Cancer Medicine, Vol 10, Iss 5, Pp 1656-1667 (2021)
Abstract Background In the new therapeutic era, comparisons between regimens containing lenalidomide and bortezomib are needed. Methods In this single‐center, prospective study, patients received four to six cycles of lenalidomide+liposomal doxorub
Externí odkaz:
https://doaj.org/article/fb8be87eeaec46ab8dd760d2d690a548
Autor:
Fengqi Liu, Hehua Wang, Junru Liu, Zhenhai Zhou, Dong Zheng, Beihui Huang, Chang Su, Waiyi Zou, Duorong Xu, Xiuzhen Tong, Juan Li
Publikováno v:
Cancer Medicine, Vol 8, Iss 11, Pp 5108-5115 (2019)
Abstract In acute myeloid leukemia (AML), myelodysplasia‐related changes contribute to a poor prognosis. This retrospective, propensity score‐matched study analyzed 108 newly diagnosed AML patients with features of myelodysplasia syndrome (MDS) (
Externí odkaz:
https://doaj.org/article/b8d347e9126f4840bdba0d415c4691f8
Autor:
Jingxuan Pan, Yingrong Lai, Qi Chen, Zhongzheng Lu, Qin Zheng, Waiyi Zou, Hui Zhang, Chao Cheng, Yanli Jin, Xianping Shi
Supplementary Data from Triptolide Inhibits Bcr-Abl Transcription and Induces Apoptosis in STI571-resistant Chronic Myelogenous Leukemia Cells Harboring T315I Mutation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67134f6cd2fdce8c9bebb9d73146e594
https://doi.org/10.1158/1078-0432.22440054.v1
https://doi.org/10.1158/1078-0432.22440054.v1
Autor:
Jingxuan Pan, Yingrong Lai, Qi Chen, Zhongzheng Lu, Qin Zheng, Waiyi Zou, Hui Zhang, Chao Cheng, Yanli Jin, Xianping Shi
Purpose: Resistance to STI571 is an emerging problem for patients with chronic myelogenous leukemia (CML). Mutation in the kinase domain of Bcr-Abl is the predominant mechanism of the acquired resistance to STI571. In the present study, we investigat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1eebfd3985603c2cf7ee6ee8e1e702e
https://doi.org/10.1158/1078-0432.c.6517431
https://doi.org/10.1158/1078-0432.c.6517431
Publikováno v:
Cancer Medicine, Vol 10, Iss 5, Pp 1656-1667 (2021)
Cancer Medicine
Cancer Medicine
Background In the new therapeutic era, comparisons between regimens containing lenalidomide and bortezomib are needed. Methods In this single‐center, prospective study, patients received four to six cycles of lenalidomide+liposomal doxorubicin+dexa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b99d2baf639f4f07e585c409a3785c9a
https://doaj.org/article/fb8be87eeaec46ab8dd760d2d690a548
https://doaj.org/article/fb8be87eeaec46ab8dd760d2d690a548
Autor:
Hong Chen, Yan Wen, Yun Zeng, LiE Lin, Xin Du, Zhenfang Liu, Bihong Sun, Hongqian Zhu, Huiqing He, Xiaotao Wang, Waiyi Zou, Caifeng Zheng, Liling Zheng, Jinxiong Huang, Liping Pang, Jixian Huang, Yuming Zhang, Haiqing Lin, Zelin Liu, Wanshou Zhu, Xuan Zhou, Qiang Wang, Xiaoli Liu, Qifa Liu, Na Xu
Publikováno v:
Blood. 140:10841-10842
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e2b65e8763e4a7f051851c702279181f
https://doi.org/10.1182/blood-2022-157246
https://doi.org/10.1182/blood-2022-157246
Publikováno v:
Current Medical Research and Opinion. 36:1807-1812
Acute myeloid leukemia (AML) is a hematopoietic stem cell malignancy and the most common type of leukemia, with the 5-year relative survival rate of 19% in Europe. Chronic myeloid leukemia (CML) is a slowly progressive clonal malignant disease, and a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::044ac5b41a7b1f2af4c8bc3dc2d387aa
https://doi.org/10.1080/03007995.2020.1808452
https://doi.org/10.1080/03007995.2020.1808452
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 21, Pp 7641-7649 (2021)
Cancer Medicine, Vol 10, Iss 21, Pp 7641-7649 (2021)
Background To evaluate the efficacy and safety of recombinant human thrombopoietin (rhTPO) for hematopoietic reconstitution after autologous stem cell transplant (ASCT) in patients with newly diagnosed multiple myeloma (NDMM). Method Thirty‐five ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3346f1c25dea98ac4562ceb2167a8b0
https://pubmed.ncbi.nlm.nih.gov/34569193
https://pubmed.ncbi.nlm.nih.gov/34569193